ArriVent BioPharma (AVBP) Consolidated Net Income (2023 - 2026)

ArriVent BioPharma has disclosed Consolidated Net Income across 4 years of filings, most recently posting -$43.3 million for Q1 2026.

• Consolidated Net Income for Q1 2026 came in at -$43.3 million, up 32.72% year-over-year; the trailing twelve-month figure through Mar 2026 was -$145.2 million (down 13.95% YoY), and the FY2025 annual result was -$166.3 million, down 106.62% from the prior year.
• Consolidated Net Income came in at -$43.3 million for Q1 2026 at ArriVent BioPharma, down from -$35.5 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of -$12.2 million in Q1 2023 to a low of -$64.4 million in Q1 2025.
• The 4-year median for Consolidated Net Income is -$21.6 million (2023), against an average of -$27.6 million.
• Across the five-year window, Consolidated Net Income tumbled 269.68% in 2025 and soared 32.72% in 2026, its largest moves.
• ArriVent BioPharma's Consolidated Net Income stood at -$21.2 million in 2023, then rose by 2.64% to -$20.6 million in 2024, then tumbled by 72.27% to -$35.5 million in 2025, then declined by 21.88% to -$43.3 million in 2026.
• The last three Consolidated Net Income figures came in at -$43.3 million (Q1 2026), -$35.5 million (Q4 2025), and -$35.0 million (Q3 2025), per Business Quant data.